Exhibit 99.1

Create the tools enabling discovery and better health O U R M I S S I O N 1 1. Preliminary unaudited full year results for 2023.​ 2. The Company is guiding full year 2023 GAAP gross margin percentage to be in the high 50’s, and non-GAAP gross margin percentage to be approximately 50%. GAAP gross margin does not include shipping and handling costs, which include freight and other activities costs associated with product shipments. Non-GAAP gross margin includes these shipping and handling costs. ​ GAAP Gross Margin2 Biomarkers Publications Revenue1 Cash burn1 : QTRX Unmatched Technology >950 Instruments installed Early penetration in multi-billion diagnostics CLIA lab running validated neuro LDTs Non-GAAP Gross Margin2

Built to lead neuro decade 2 Strong Results Operational Leverage Clear Strategy Research Power the neuro decade with unique biomarkers Diagnostics Establish and grow the AD diagnostics business Lab Services capability >0.75M tests per year (improvement of 50%) Manufacturing capacity >4M tests per year (improvement of 300%) Innovation rate >20 assays per year (development times reduced from >18 months to <6 months) Double digit top-line growth1 Non-GAAP GM2 of appr. 50% Improvement of 1200 bps Strong Balance Sheet >$300M1 in net cash Annual cash burn1 down by >3x 1. Preliminary unaudited full year results for 2023.​ 2. The Company is guiding full year 2023 GAAP gross margin percentage to be in the high 50’s, and non-GAAP gross margin percentage to be approximately 50%. GAAP gross margin does not include shipping and handling costs, which include freight and other activities costs associated with product shipments. Non-GAAP gross margin includes these shipping and handling costs. ​